VLA Vela Minerals Ltd

0.145

0.00 (0.00%)

27 Dec 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Vela Minerals Ltd	TSXV:VLA	TSX Venture	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	0.145	0.145	0.18				0	00:00:00

VALNEVA Announces Approval of an EB66(R)-based Prototype Influenza Vaccine in Japan

26/03/2015 6:56am

GlobeNewswire Inc.

Vela Minerals (TSXV:VLA)
Historical Stock Chart

From Dec 2019 to Dec 2024

Click Here for more Vela Minerals Charts.

The vaccine was developed by the Chemo-Sero Therapeutic Research Institute (Kaketsuken) in collaboration with GlaxoSmithKline using Valneva's EB66® cell line, this represents a potential of 80 million vaccine doses to be produced in the event of a pandemic.

To download the full press release, please click on the following icon:

2015_03_26 Valneva CC Prototype Flu Vaccine ENG http://hugin.info/143334/R/1906344/678670.pdf 2015_03_26 Valneva CC Prototype Flu Vaccine FRA http://hugin.info/143334/R/1906344/678672.pdf 2015_03_26 Valneva CC Prototype Flu Vaccine GER http://hugin.info/143334/R/1906344/678673.pdf

HUG#1906344

CONTACT: Florence Hocdee- Leroy
         T: +33 (0)228 07 37 10
         M: +33 642 04 42 14
         
         Teresa Pinzolits
         T: +43-1-206 20-1116
         M: +43 676 845567357
         
         Communications@valneva.com